<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048476</url>
  </required_header>
  <id_info>
    <org_study_id>NSFC30872113</org_study_id>
    <nct_id>NCT01048476</nct_id>
  </id_info>
  <brief_title>Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration</brief_title>
  <official_title>Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lutein is one of oxygenated carotenoids. Over the past few years, there has been increased&#xD;
      interest in evaluating the effect of lutein for optimizing eye health. A large number of&#xD;
      epidemiological studies support the notion that the high intake dietary of lutein is strongly&#xD;
      associated with a decreased relative risk of AMD.Moreover, findings from initial&#xD;
      observational studies have now been followed by placebo-controlled intervention trials&#xD;
      showing that dietary modification and supplementation with lutein result in increasing the&#xD;
      macular pigment optical density, and may help to improve visual function in patients&#xD;
      suffering from AMD.Currently, nutritional status and background information of lutein and&#xD;
      zeaxanthin in Chinese population is lack. Little is known about the preventive and therapy&#xD;
      benefits of lutein on visual function in the AMD populations. In particular, the effect on&#xD;
      visual function of relatively certain doses of lutein and zeaxanthin is unknown. Therefore,&#xD;
      the objective of the present study was to examine the effect of consuming different doses of&#xD;
      lutein on MPOD and visual function in AMD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We aim to study the effect and the mechanism of lutein in the prevention and treatment for&#xD;
      age-related macular degeneration (AMD). Using the cluster sampling method, baseline&#xD;
      characteristics screening will be performed in Han nationality men and women in the suburban&#xD;
      areas of Beijing, ranging in age from 50 to79 years. According to clinical diagnosis standard&#xD;
      of AMD, AMD (n=120) and normal subjects (n=40) will be randomly selected to measure serum&#xD;
      lutein and nutritional status, and evaluate the relationship between lutein and AMD. Each&#xD;
      subject of AMD will be randomly assigned to 1 of 4 groups: Group low lutein (Group LL); Group&#xD;
      high lutein (Group HL); Group lutein/zeaxanthin (Group LZ); and Group Placebo to participate&#xD;
      in the randomized, double-blind, placebo-controlled, 1 year intervention study, respectively.&#xD;
      Macular pigment optical density,related symptoms and multifocal electroretinogram (mfERG)&#xD;
      will be measured at at weeks 0, 24 and 48, to compare their dynamic changes in response to&#xD;
      supplements at baseline and each follow-up visit, observe time- and dose-response correlation&#xD;
      of supplementation with lutein, assess the efficacy, dosage of lutein and/or zeaxanthin&#xD;
      supplement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">April 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MPOD and multifocal electroretinograms</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the safety and efficacy of lutein in reducing the risk of the development of advanced AMD.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Group L20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: 20mg Lutein; daily supplementation one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group L10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: 10mg Lutein; daily supplementation one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement: Placebo, 0 mg Lutein</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator: Group LZ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lutein</intervention_name>
    <description>Dietary Supplement: 20mg Lutein; daily supplementation one year</description>
    <arm_group_label>Group L20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lutein</intervention_name>
    <description>Dietary Supplement: 10mg Lutein; daily supplementation one year</description>
    <arm_group_label>Group L10</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Dietary Supplement: placebo; daily supplementation one year</description>
    <arm_group_label>Group Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lutein and zeaxanthin</intervention_name>
    <description>Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year</description>
    <arm_group_label>Active Comparator: Group LZ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with nonexudative AMD (either categories 2, 3 or 4 according to the AREDS&#xD;
             criteria; in group 4 the eyes with no-advanced AMD will be included)&#xD;
&#xD;
          -  Age between 50 and 90 years&#xD;
&#xD;
          -  Able to understand and comply with the requirements of the trial&#xD;
&#xD;
          -  Visual acuity &gt; 0.4&#xD;
&#xD;
          -  Subjects must agree to take only the nutritional supplement that is&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently enrolled in an ophthalmic clinical trial&#xD;
&#xD;
          -  Eyes with concomitant macular or choroidal disorders other than AMD and with&#xD;
             indefinite signs of AMD&#xD;
&#xD;
          -  Eyes with a diagnosis of exudative AMD with active subretinal neovascularization&#xD;
             (SRNV) or CNV lesions requiring laser photocoagulation in the study eye&#xD;
&#xD;
          -  Subjects with significant ocular lens opacities causing vision decrease&#xD;
&#xD;
          -  Subjects with amblyopia&#xD;
&#xD;
          -  Subjects with optic nerve disease (neuropathy, atrophy, papilledema), unstable&#xD;
             glaucoma as defined by intraocular pressures greater than 25 mm Hg, 3 or more glaucoma&#xD;
             medications, C/D of 0.8 or greater and visual fields consistent with glaucoma; history&#xD;
             of retina-vitreous surgery, degenerative myopia, active posterior intraocular&#xD;
             inflammatory disease, chronic use of topical ocular steroid medications,&#xD;
             vasoproliferative retinopathies (other than AMD), rhegmatogenous retinal detachment,&#xD;
             and inherited macular dystrophies&#xD;
&#xD;
          -  Subjects with demand type pacemakers or epilepsy&#xD;
&#xD;
          -  Subjects with uncontrolled hypertension (defined as diastolic of 90 or greater and&#xD;
             systolic of 150 or greater)&#xD;
&#xD;
          -  Subjects with recent history (within the previous year) of cerebral vascular disease&#xD;
&#xD;
          -  manifested with transient ischemic attacks (TIA's) or cerebral vascular accidents&#xD;
             (CVA's)&#xD;
&#xD;
          -  Subjects with a history of AIDS&#xD;
&#xD;
          -  lutein supplementation within the last 3 months&#xD;
&#xD;
          -  Subjects who have had intraocular surgery in trial eye within 3 months prior to&#xD;
             enrolling in the trial&#xD;
&#xD;
          -  Patients who are unwilling to adhere to visit examination schedules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking university</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>le Ma, MD</last_name>
      <email>male@bjmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Le MA</investigator_full_name>
    <investigator_title>MAL</investigator_title>
  </responsible_party>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

